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Abstract
Convincing epidemiologic evidence indicates that physical activity is inversely
associated with breast cancer risk. Whether this association varies by the tumor
protein expression status of the estrogen receptor (ER), progesterone receptor
(PR), human epidermal growth factor receptor 2 (HER2), or p53 is unclear.
We evaluated the effects of recreational physical activity on risk of invasive
breast cancer classified by the four biomarkers, fitting multivariable uncondi-
tional logistic regression models to data from 1195 case and 2012 control par-
ticipants in the population-based Women’s Contraceptive and Reproductive
Experiences Study. Self-reported recreational physical activity at different life
periods was measured as average annual metabolic equivalents of energy expen-
diture [MET]-hours per week. Our biomarker-specific analyses showed that life-
time recreational physical activity was negatively associated with the risks of
ER-positive (ER+) and of HER2-negative (HER2) subtypes (both
Ptrend ≤ 0.04), but not with other subtypes (all Ptrend > 0.10). Analyses using
combinations of biomarkers indicated that risk of invasive breast cancer varied
only by HER2 status. Risk of HER2–breast cancer decreased with increasing
number of MET-hours of recreational physical activity in each specific life per-
iod examined, although some trend tests were only marginally statistically sig-
nificant (all Ptrend ≤ 0.06). The test for homogeneity of trends (HER2– vs.
HER2+ ) reached statistical significance only when evaluating physical activity
during the first 10 years after menarche (Phomogeneity = 0.03). Our data suggest
that physical activity reduces risk of invasive breast cancers that lack HER2
overexpression, increasing our understanding of the biological mechanisms by
which physical activity acts.
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Introduction
Convincing epidemiologic evidence indicates that physical
activity is inversely associated with breast cancer risk with
an average decrease in risk of 25–30% for women in the
highest versus the lowest category of physical activity [1].
Although previous studies have examined whether the
physical activity-breast cancer association varies by the
tumor protein expression status of the estrogen receptor
(ER) and the progesterone receptor (PR) [2–23], little is
known as to whether the association varies by the human
epidermal growth factor receptor 2 (HER2) or p53.
Several biological mechanisms have been proposed that
may account for the association between physical activity
and breast cancer [24–29]. Physical activity may reduce a
woman’s cumulative exposure to biologically available
estrogens by delaying the onset of menarche, reducing the
number of ovulatory cycles she experiences, or decreasing
body fat, which would decrease the aromatization of
androgens thereby reducing estrogens levels [30]. Estro-
gens are mitogens in breast tissue, stimulating mammary
cell proliferation which increases the chance of random
genetic mutations through ER activation [31, 32]. Due to
the possible involvement of hormone-related mechanisms,
the associations between physical activity and breast can-
cer have been evaluated by ER status, or ER and PR sta-
tus jointly [2–23]. The majority of these studies found
that physical activity was associated with a lower risk of
breast cancer regardless of ER or ER/PR [7–21]. Five
studies observed a statistically significant association of
physical activity with lower breast cancer risk only among
women with ER-positive (ER+) or ER+ plus PR-positive
(PR+) [2–6]. In two studies, physical activity was associ-
ated with a reduction in breast cancer risk only for
women with ER-negative (ER) breast cancer [22, 23].
Gene expression studies with cDNA microarray tech-
nology have demonstrated that triple negative (TN, ER/
PR as well as human epidermal HER2-negative,
HER2) breast cancers are often characterized by a basal-
like molecular profile, which exhibits overexpression of a
number of genes involved in cell proliferation and differ-
entiation, p-21 mediated pathway, and G1-S checkpoints
of cell cycle signaling pathways; whereas ER/PR+/HER2
and ER/PR+/HER2+ are often characterized by luminal
molecular profiles, which are associated with the ER sig-
naling pathway [33, 34]. Note that we use the notation
“ER/PR+” to represent “ER+ and/or PR+” throughout
this article. Owing to the different pathways identified for
different breast cancer subtypes, the inverse association of
physical activity with breast cancer could vary by subtype
defined by ER, PR, and HER2 status. The findings from
three epidemiologic studies on this topic are mixed [3,
35, 36].
Little is known about p53 status and the physical activ-
ity-breast cancer association. Among mice with a single
defective p53 allele, treadmill running exercise was associ-
ated with an increased rate of mammary tumor develop-
ment [37]. Yet, no epidemiologic data have been
published prior to 2015 regarding this association.
We previously reported that risk of both ER+ and ER
invasive breast cancer decreased with increasing levels of
recreational physical activity using data from the five
study sites of the Women’s Contraceptive and Reproduc-
tive Experiences (CARE) Study [10]. In a sub-study
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conducted at two of the participating Women’s CARE
study sites, where tumor tissue was collected, we showed
that hormone-related risk factors (e.g., number of full-
term pregnancies and age at first full-term pregnancy)
were associated with the risk of ER/PR+/HER2 breast
cancer, but not with TN breast cancer [38]. Here we
examine whether the benefits of physical activity vary by
the tumor protein expression status of ER, PR, HER2,
and p53 in order to provide greater insight into biological
mechanisms underlying the association between physical
activity and risk of breast cancer.
Materials and Methods
Study population and data collection
The participants for this analysis include women from
Detroit and Los Angeles (LA), two of the five participat-
ing sites (Atlanta, Detroit, LA, Philadelphia, Seattle) in
the Women’s CARE Study [39]. The Women’s CARE
Study, which was supported by National Institute of
Child Health and Human Development (NICHD), was a
population-based, case–control study designed to examine
risk factors for invasive breast cancer among US-born
white women and black women [39]. The age distribution
and participant response rates by study site, case–control
status and race have been published [39]. Tissue collec-
tion, as part of the Women’s CARE Study, was supported
by NICHD for the Detroit and LA study sites, as advised
by the Women’s CARE Steering Committee [39].
Case participants in the Women’s CARE Study had no
prior diagnosis of invasive or in situ breast cancer and
were diagnosed with their first primary invasive breast
cancer (International Classification of Diseases for Oncol-
ogy codes C50.0–C50.9) between July 1994 and April
1998. Control participants were women with no history
of invasive or in situ breast cancer who were identified by
random digit dialing. Control participants were frequency
matched to the expected distribution of cases in strata
defined by 5 year age groups, ethnicity (white or black),
and residence located in the same geographic (study)
region. The Women’s CARE Study recruited 1921 case
and 2034 control participants from Detroit and LA. The
interview response rates were 74.7% for cases in Detroit,
74.1% for controls in Detroit, 73.3% for cases in LA, and
73.7% for controls in LA. All participants for this study
provided written informed consent and the study proto-
col was approved by the Institutional Review Boards at
the University of Southern California (USC), the Karm-
anos Cancer Institute Center, the Centers for Disease
Control and Prevention, and the City of Hope.
The Women’s CARE Study collected demographic
characteristics, detailed information about current and
past recreational physical activity, menstrual and repro-
ductive history, family history of breast cancer, body size
measures including height and weight, history of oral
contraceptive use, and information pertaining to other
factors from each participant during an in-person inter-
view conducted from August 1994 through December
1998. Information was recorded up to a predetermined
reference date for each participant. The reference date
was the date of diagnosis for women with breast cancer
or the date of the initial telephone screening of the
household for control participants.
Measures of recreational physical activity
Details regarding the measures of recreational physical
activity in the Women’s CARE Study have been published
elsewhere [10]. Briefly, the Women’s CARE Study docu-
mented all episodes of exercise activity in which a partici-
pant engaged throughout her lifetime up to her reference
date, and recorded details of activities in chronologic order
starting with the first activity recalled by the respondent.
The information collected for each activity episode
included the type of activity, the age at which the woman
started and stopped the activity, the number of months per
year of participation in the activity, and average duration
in hours per week. The activities reported included any
organized sports activities, such as school sports or teams,
and individual activities, such as walking, jogging, running,
hiking, bicycling, aerobics, swimming, and dancing. The
details as to the extent of the activity were also recorded.
For example, for swimming, we collected the types of
swimming including recreational swimming, snorkeling,
swimming laps, or training for competitive swimming.
The average number of hours of exercise activity per
week for each year of age for each participant was esti-
mated. Women were considered to be inactive at any
given age if they reported no activity for that age or if
their average number of hours per week of activity for
that age was less than 0.67 h (i.e., equivalent to less than
2 h/week for 4 months). The metabolic equivalents of
energy expenditure (MET)-hours per week for each age
were estimated by multiplying together the number of
hours per week a woman spent in a particular activity,
the proportion of the year spent in that activity, and the
estimated MET score for the activity based on the Com-
pendium of Physical Activity [40]. A measure of lifetime
activity was defined as average annual exercise activity
from age 10 years to the woman’s age on her reference
date in hours per week and in MET-hours per week. The
average number of MET-hours per week was also assessed
for the following specific times: the first 10 years after
menarche, ages 10–19 years, ages 20–34 years, and the
10 years before each woman’s reference date.
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Assessment of biomarkers
Paraffin-embedded tumor blocks were obtained from
pathology laboratories where diagnoses were made for
1333 participating breast cancer cases (Detroit: 414, LA:
919). Approximately 80% of the blocks requested
were received. Tumor blocks were carefully reviewed
and processed in the centralized pathology laboratory of
Dr. Michael F. Press at USC.
We excluded 113 tumor samples because the tumor
blocks contained either no tumor tissue (n = 46), insuffi-
cient tissue for the laboratory assays (n = 3), only carcinoma
in situ (n = 56), or only hematoxylin and eosin-stained
tissue sections (n = 8); we also excluded 14 samples that
had other problems that made evaluation of the tumor ER,
PR, HER2, or p53 difficult. Expression of ER, PR, HER2,
and p53 was determined for 1206 samples (Detroit: 367,
LA: 839).
ER and PR expression was determined using previously
published immunohistochemistry (IHC) methods [41,
42]. Immunostaining results for ER and PR expression
were interpreted in a blind fashion and scored semi-quan-
titatively on the basis of the visually estimated percentage
of positively stained tumor cell nuclei. At least 100 tumor
cells were examined for each specimen and samples with
≥1% of immunostained tumor cell nuclei were considered
positive for ER and PR [43].
HER2 expression was determined by IHC using the
10H8 monoclonal antibody [44] to assess HER2 mem-
brane protein immunostaining. Immunostaining results
for HER2 were categorized as no (0) or weak (1+),
moderate (2+), and strong (3+) membrane immuno-
staining. No (0) or weak (1+) membrane immunostain-
ing was classified as low HER2 expression (HER2)
whereas moderate (2+) or strong membrane immuno-
staining (3+) was classified as HER2 overexpression
(HER2+). This was based on previous validation results
from the same pathology laboratory, indicating that the
agreement between 10H8-IHC and fluorescent in situ
hybridization (FISH) analysis was 92%; discordant
results were found for 5.7% of tumor samples, which
scored as 0 or 1+ by 10H8-IHC, but showed HER2 gene
amplification; and 2.1% of tumor samples, which scored
as 2+ or 3+ by 10H8-IHC, but showed no HER2 gene
amplification [44].
The expression of p53 protein was determined by IHC
using the monoclonal mouse antibody DO7 (Oncogene
Science, Inc. Cambridge, MA) and BP 53-12-1 (Biogenex,
San Ramon, CA) to measure p53 nuclear protein immu-
nostaining. Based on findings from previous studies, com-
paring p53 mutations in exons 2–11 with p53 protein
expression levels [45, 46], ≥10% nuclear staining for p53
protein was deemed positive [47].
Statistical analyses
We used Pearson Chi-squared tests to compare frequency
distributions of categorical variables. Because of the non-
normal distributions of age at reference date and body
mass index (BMI) 5 years before the reference date, we
conducted the nonparametric Wilcoxon test to evaluate
differences in these two variables between case partici-
pants and control participants.
For case–control comparisons, we fit multivariable
polychotomous unconditional logistic regression models
[48] to data to estimate the odds ratios (ORs) and corre-
sponding 95% confidence intervals (CIs) of breast cancer
associated with lifetime recreational physical activity (1)
by the expression status of each individual receptor for all
women, premenopausal women, and postmenopausal
women, (2) by various combinations of ER, PR and
HER2 status including two common subtypes (TN and
ER/PR+/HER2), which were further stratified by p53
status, and (3) by three levels of HER2 expression (none/
weak, moderate, strong expression). We also examined
the association between time-period-specific or age-spe-
cific recreational physical activity and breast cancer risk
according to HER2 status. Moreover, since differential
recall of detailed physical activity history between cases
and controls might occur, we conducted case–case com-
parisons for ER versus ER+, PR versus PR+, HER2
versus HER2+, and p53 versus p53+ patients using a
multivariable unconditional logistic regression approach
[48].
We used previously published categories of average
MET-hours per week of physical activity (less than or
equal to 2.2, 2.3 to 6.6, 6.7 to 15.1, or at least 15.2 annual
MET hour/week), which were generated according to
approximate quartiles of the distribution of all Women’s
CARE Study control participants classified as active [10].
We included the following factors, selected a priori, as
potential confounders in all multivariable logistic regres-
sion models: study site (Detroit or LA), race (white or
black), education (high school graduate or a lower level
of education, attended technical school or college, but did
not graduate, or college graduate), age (in 5 year age
groups from 35–39 to 60–64), family history of breast
cancer [first-degree (mother, sister, or daughter); no first-
degree family history including 4% of participants with
uncertain answers], age at menarche (less than or equal
to 11, 12, 13, or at least 14 years), parity (nulligravid,
pregnant but no full-term pregnancy, or parity 1, 2, 3, or
4+), a four-category variable combining menopausal sta-
tus and hormone therapy (HT) use (premenopausal,
postmenopausal and never HT use, postmenopausal and
ever HT use, or unknown menopausal status), BMI
five years before the reference date (continuous variable,
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kg/m2), duration of OC use (never, less than 1 year, 1–
4 years, 5–9 years, or at least 10 years). When we exam-
ined the association between time-period-specific or age-
specific recreational physical activity and breast cancer
risk, we did not mutually adjust time-period-specific and
age-specific physical activity as some of the periods over-
lap and, in addition, physical activity measures are highly
correlated (e.g., the Spearman correlation coefficient for
average-annual MET-hours/wk of physical activity at ages
10–19 years and 20–34 years was 0.69); we included
women who engaged in recreational physical activity only
in other time periods or other age groups as a separate
category.
Tests for trend were conducted by fitting ordinal values
corresponding to categories of recreational physical activ-
ity in our models and testing whether the coefficient
(slope of the dose response) differed from zero. When
conducting tests for trend for time-period-specific or age-
specific physical activity variables, we excluded women
who engaged in recreational physical activity only in
other time periods or other age groups. We also con-
ducted Wald chi-square tests for homogeneity of the asso-
ciations with recreational physical activity across different
subtypes of breast cancer by fitting a model using ordinal
values.
We excluded 11 case participants and 22 control partic-
ipants with missing information on physical activity (2
cases, 3 controls), parity (1 case, 4 controls), BMI (4
cases, 9 controls), or OC use (4 cases, 6 controls). This
resulted in 1195 cases (581 premenopausal, 497 postmen-
opausal, and 117 with unknown menopausal status) and
2012 controls available for the current analysis (929 pre-
menopausal, 831 postmenopausal, and 252 with unknown
menopausal status). Among 1328 postmenopausal
women, 827 women (307 cases, 520 controls) reported
having ever used HT.
When reporting the results of univariate comparisons
between case participants and control participants, trend
tests, or homogeneity tests, we considered a two-sided P
value less than 0.05 as statistically significant. We did not
adjust P values for multiple comparisons as these analyses
were considered as exploratory [49]. All analyses were
performed using the SAS statistical package (Version 9.2,
SAS Institute, Cary, NC).
Results
Characteristics of cases and controls
Overall, case participants were more likely than control
participants to be better educated (Pv2 = 0.01), to have a
first-degree breast cancer family history (Pv2 < 0.0001),
and to never have been pregnant (Pv2 = 0.02) (Table 1).
The case–control differences in education and pregnancy
history were restricted to LA women, whereas the differ-
ence in first-degree breast cancer family history was
observed for both LA and Detroit women.
Associations of breast cancer defined by the
status of individual receptors with lifetime
recreational physical activity
As previously reported among all participants of the
Women’s CARE Study [50], lifetime recreational physical
activity was associated with a decreased risk of ER and
ER+ breast cancer, but only the result for ER+ disease
was statistically significant in our sample of LA and
Detroit women (Ptrend = 0.67 for ER vs. Ptrend = 0.03
for ER+, Table 2). Analyses by HER2 status showed that
the ORs of HER2 breast cancer declined with increasing
lifetime MET-hours of physical activity (Ptrend = 0.04),
whereas no trend was observed for HER2+ breast cancer
(Ptrend = 0.93). Homogeneity tests of trends neither
between ER and ER+ nor between HER2 vs. HER2+
was statistically significant (both Phomogeneity of
trends ≥ 0.19). Our data showed no evidence of an associa-
tion between recreational physical activity and breast can-
cer risk that varied according to PR or p53 protein status.
Although HER2 cases did not differ statistically from
HER2+, HER2 cases were less likely to have engaged in
recreational physical activity. Moreover, the results
observed for all participants are likely driven by those of
premenopausal women since we did not observe any
association among postmenopausal women (Table S1).
Associations of breast cancer defined by
combinations of biomarkers with lifetime
recreational physical activity
Analyses by the status of ER and HER2 jointly showed
that lifetime MET-hours of physical activity were associ-
ated with decreased risks for the HER2 subtypes
(ER/HER2 and ER+/HER2 breast cancers), but
only the result for ER+/HER2 was statistically signifi-
cant (Table 3, Ptrend = 0.01 for ER+/HER2). Our data
did not provide any evidence that lifetime MET-hours
of physical activity was associated with a reduced risk
for HER2+ subtypes including ER/HER2+ and ER+/
HER2+ breast cancer (both Ptrend ≥ 0.88). However, we
found no difference in the trends across subtypes
defined by ER and HER2 (test for homogeneity of
trends: P = 0.38).
Analyses combining ER, PR, and HER2 also demon-
strated that lifetime MET-hours of physical activity were
inversely associated with the risk for HER2 subtypes,
especially for ER/PR+/HER2 subtype (Ptrend = 0.02),
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Table 1. Characteristics of invasive breast cancer patients and control participants from Detroit and Los Angeles components of the Women’s
CARE Study.












(n = 834) P-value1
Race
White 57.1% 56.6% 0.77 57.7% 62.1% 0.17 56.7% 54.2% 0.26
Black 42.9% 43.4% 42.3% 38.0% 43.3% 45.8%
Education
≤High school 40.0% 35.9% 0.01 46.2% 44.9% 0.54 36.2% 32.0% 0.05
Technical school or some college 33.7% 38.7% 30.1% 33.2% 35.9% 41.0%
College graduate 26.3% 25.4% 23.7% 21.9% 27.9% 27.0%
Mean age at reference
date (SD), years
48.9 (8.4) 49.0 (8.6) 0.672 49.0 (8.5) 48.7 (8.8) 0.562 48.8 (8.4) 49.1 (8.5) 0.352
First-degree breast
cancer family history
8.2% 15.6% <0.0001 9.3% 17.2% 0.0001 7.5% 14.9% <0.0001
Age at menarche, years
≤11 28.5% 25.6% 0.17 29.3% 26.6% 0.70 28.0% 25.2% 0.31
12 25.9% 27.2% 25.4% 26.6% 26.2% 27.5%
13 25.6% 28.2% 26.1% 28.5% 25.3% 28.1%
≥14 20.0% 19.0% 19.2% 18.3% 20.6% 19.3%
Number of full-term (>26 week) pregnancies
Never pregnant 8.8% 11.2% 0.02 8.3% 10.0% 0.91 9.0% 11.8% 0.02
Only non-full-term pregnancy 7.9% 7.2% 5.1% 5.3% 9.6% 8.0%
1 15.6% 17.9% 15.7% 17.2% 15.6% 18.2%
2 28.5% 29.6% 29.4% 28.0% 28.0% 30.3%
3 19.4% 17.3% 19.8% 19.1% 19.1% 16.6%
≥4 19.9% 16.7% 21.7% 20.5% 18.8% 15.1%
Menopausal status
Premenopausal 46.2% 48.6% 0.12 46.0% 49.3% 0.12 46.3% 48.3% 0.21
Postmenopausal
Never HT use 15.5% 15.9% 17.6% 21.3% 14.1% 13.6%
Ever HT use 25.8% 25.7% 24.1% 19.7% 26.9% 28.3%
Unknown 12.5% 9.8% 12.2% 9.7% 12.7% 9.8%
Mean body mass index 5 years
before reference date (SD), years
26.1 (6.0) 26.0 (5.8) 0.882 26.2 (6.1) 26.1 (6.0) 0.662 26.0 (6.0) 26.0 (5.7) 0.842
Duration of oral contraceptive use, years
Never 20.3% 21.2% 0.84 17.9% 23.3% 0.18 21.8% 20.3% 0.78
<1 17.7% 17.7% 16.6% 15.2% 18.5% 18.8%
1–4 26.8% 26.6% 28.4% 29.9% 25.9% 25.2%
5–9 19.7% 18.2% 21.7% 18.0% 18.5% 18.4%
≥10 15.5% 16.2% 15.4% 13.6% 15.5% 17.4%
ER
Negative 42.0% 44.0% 41.1%
Positive 58.0% 56.0% 58.9%
PR
Negative 44.6% 46.5% 43.8%
Positive 55.4% 53.5% 56.2%
HER2
Negative 81.9% 84.8% 80.7%
Positive 18.1% 15.2% 19.3%
P53
Negative 72.1% 80.6% 68.4%
Positive 27.9% 19.4% 31.6%
SD, standard deviation.
1P-value ascertained from Pearson v2 test, except where otherwise noted.
2P-value from nonparametric Wilcoxon tests.
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but were not associated with HER2+ subtypes (HER2-
enriched, ER/PR+/HER2+; both Ptrend ≥ 0.84). The differ-
ence in trends across the four subtypes defined by ER/PR/
HER2 was not statistically significant (test for homogene-
ity of trends: P = 0.52). Subclassification of two common
subtypes (TN and ER/PR+/HER2) by p53 status did not
further differentiate the associations of these subtypes
with recreational physical activity (test for homogeneity
of trends: P = 0.44, results not shown). We assessed
whether lifetime recreational physical activity was associ-
ated with breast cancer with each level of HER2 expres-
sion (negative/weakly positive, moderately positive,
strongly positive; Table S2). This analysis showed that the
ORs of HER2 breast cancer declined with increasing
lifetime MET-hours of physical activity (Ptrend = 0.04),
but no association was observed for breast cancers that
were either moderate or strong expressers of HER2 (both
Ptrend ≥ 0.76).


















Cases sub-grouped by ER status
Inactive 500 136 171 Referent Referent Referent
≤2.2 373 76 132 0.78 (0.57–1.07) 0.95 (0.72–1.25) 0.79 (0.54–1.15)
2.3–6.6 369 102 148 1.02 (0.75–1.38) 1.03 (0.78–1.35) 0.98 (0.68–1.40)
6.7–15.1 374 88 127 0.85 (0.62–1.17) 0.83 (0.63–1.10) 1.00 (0.68–1.47)
≥15.2 396 100 115 0.91 (0.67–1.24) 0.73 (0.55–0.98) 1.29 (0.88–1.89)
Trend P-value 0.67 0.03 0.14
Homogeneity of trends for
case–control comparison
P = 0.19
Cases sub-grouped by PR status
Inactive 500 148 159 Referent Referent Referent
≤2.2 373 91 117 0.87 (0.65–1.18) 0.88 (0.67–1.17) 0.95 (0.65–1.37)
2.3–6.6 369 107 143 1.00 (0.74–1.34) 1.04 (0.79–1.38) 0.92 (0.65–1.31)
6.7–15.1 374 90 125 0.80 (0.59–1.10) 0.86 (0.65–1.15) 0.91 (0.62–1.32)
≥15.2 396 97 118 0.81 (0.60–1.10) 0.81 (0.60–1.08) 1.02 (0.70–1.48)
Trend P-value 0.15 0.17 0.94
Homogeneity of trends for
case–control comparison
P = 0.91
Cases sub-grouped by HER2 status
Inactive 500 258 49 Referent Referent Referent
≤2.2 373 169 39 0.83 (0.65–1.06) 1.14 (0.72–1.78) 0.75 (0.46-1.21)
2.3–6.6 369 201 49 0.96 (0.75–1.21) 1.38 (0.89–2.13) 0.73 (0.46-1.16)
6.7–15.1 374 173 42 0.77 (0.60–0.99) 1.18 (0.75–1.87) 0.61 (0.38-1.00)
≥15.2 396 178 37 0.77 (0.60–0.99) 0.98 (0.61–1.58) 0.75 (0.45-1.24)
Trend P-value 0.04 0.93 0.14
Homogeneity of trends for
case–control comparison
P = 0.23
Cases sub-grouped by p53 status
Inactive 500 213 94 Referent Referent Referent
≤2.2 373 149 59 0.88 (0.68–1.14) 0.89 (0.62–1.27) 1.03 (0.68–1.54)
2.3–6.6 369 185 65 1.08 (0.84–1.39) 0.91 (0.63–1.30) 1.21 (0.82–1.80)
6.7–15.1 374 164 51 0.91 (0.70–1.18) 0.67 (0.46–0.98) 1.43 (0.93–2.19)
≥15.2 396 150 65 0.81 (0.62–1.06) 0.81 (0.56–1.16) 0.96 (0.64–1.46)
Trend P-value 0.20 0.11 0.59
Homogeneity of trends for
case–control comparison
P = 0.50
OR, odds ratio; CI, confidence interval; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2.
1Adjusted for study site, race, education, age, family history of breast cancer, age at menarche, parity, a four-category variable combining meno-
pausal status and hormone therapy use, body mass index, and the duration of oral contraceptive use.
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Associations of breast cancer defined by
HER2 status with recreational physical
activity in which a woman engaged during
specific time periods or age periods
HER2–breast cancer was inversely associated with the
MET-hours of physical activity for each specific time per-
iod of life that we examined, although some tests for
trend were only marginally statistically significant
(Table 4, all Ptrend ≤ 0.06). No associations were found
for HER2+ breast cancers (all Ptrend ≥ 0.25). The differ-
ence in trends between HER2 and HER2+ breast cancer
was statistically significant for recreational physical activ-
ity only in the first 10 years after menarche (test for
homogeneity of trends: P = 0.03) and was marginally sta-
tistically significant for physical activity in which the
Table 4. Multivariable adjusted1 OR and 95% CI for invasive breast cancer defined by HER2 status with recreational physical activity in specific
time periods or age periods.
Average exercise activity
(annual MET h/week)












First 10 years after menarche
Inactive2 504 260 49 Referent Referent Referent
≤2.2 97 44 5 0.82 (0.55–1.22) 0.54 (0.21–1.42) 1.54 (0.57–4.19)
2.3–6.6 186 94 30 0.85 (0.63–1.15) 1.69 (1.02–2.80) 0.55 (0.32–0.94)
6.7–15.1 241 120 28 0.84 (0.64–1.11) 1.25 (0.75–2.08) 0.67 (0.39–1.16)
≥15.2 412 187 43 0.77 (0.60–0.98) 1.10 (0.70–1.74) 0.67 (0.41–1.08)
Trend P-value 0.05 0.25 0.02
Homogeneity of trends for case–control comparison P = 0.03
Exercise only in other time period(s) 572 274 61 0.87 (0.70–1.08) 1.17 (0.78–1.75) 0.74 (0.48–1.14)
Ages 10–19 years
Inactive3 500 258 49 Referent Referent Referent
≤2.2 76 49 9 1.13 (0.75–1.68) 1.22 (0.57–2.64) 0.95 (0.42–2.12)
2.3–6.6 195 83 22 0.71 (0.52–0.97) 1.19 (0.68–2.07) 0.57 (0.31–1.02)
6.7–15.1 221 109 19 0.80 (0.60–1.07) 0.87 (0.49–1.55) 0.91 (0.50–1.66)
≥15.2 409 187 45 0.78 (0.61–1.00) 1.14 (0.73–1.80) 0.67 (0.41–1.08)
Trend P-value 0.02 0.53 0.05
Homogeneity of trends for case–control comparison P = 0.06
Exercise only in other age group(s) 611 293 72 0.87 (0.71–1.08) 1.27 (0.85–1.87) 0.70 (0.46–1.06)
Ages 20–34 years
Inactive3 500 258 49 Referent Referent Referent
≤2.2 164 76 10 0.82 (0.59–1.13) 0.63 (0.31–1.29) 1.43 (0.67–3.04)
2.3–6.6 225 131 33 1.03 (0.78–1.36) 1.54 (0.95–2.52) 0.66 (0.39–1.11)
6.7–15.1 286 148 29 0.89 (0.68–1.16) 1.02 (0.61–1.69) 0.83 (0.49–1.42)
≥15.2 365 151 33 0.72 (0.56–0.93) 0.92 (0.57–1.50) 0.76 (0.45–1.27)
Trend P-value 0.03 0.85 0.11
Homogeneity of trends for case–control comparison P = 0.20
Exercise only in other age group(s) 472 215 62 0.81 (0.64-1.02) 1.44 (0.95-2.17) 0.56 (0.36-0.87)
10 years before reference date
Inactive3 500 258 49 Referent Referent Referent
≤2.2 188 90 19 0.89 (0.66–1.21) 1.06 (0.60–1.86) 0.89 (0.48–1.62)
2.3–6.6 277 140 32 0.88 (0.67–1.14) 1.26 (0.78–2.05) 0.70 (0.42–1.17)
6.7–15.1 333 172 42 0.90 (0.70–1.16) 1.31 (0.84–2.06) 0.69 (0.43–1.12)
≥15.2 441 200 45 0.78 (0.62–0.99) 1.09 (0.70–1.71) 0.67 (0.42–1.09)
Trend P-value 0.06 0.55 0.07
Homogeneity of trends for case–control comparison P = 0.12
Exercise only in other time period(s) 273 119 29 0.74 (0.56–0.98) 1.11 (0.67–1.83) 0.69 (0.40–1.17)
OR, odds ratio; CI, confidence interval. HER2, human epidermal growth factor receptor 2.
1Adjusted for study site, race, education, age, family history of breast cancer, age at menarche, parity, a four-category variable combining meno-
pausal status and hormone therapy use, body mass index, and the duration of oral contraceptive use.
2Inactive between age at menarche and reference date.
3Inactive between age 10 years and reference date.
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woman engaged at ages 10–19 years (test for homogeneity
of trends: P = 0.06), whereas the trends in risk did not
differ statistically for activity at ages 20–34 or 10 years
before reference date (both tests for homogeneity of
trends: P ≥ 0.12).
When we compared HER2 cases with HER2+ cases,
ORs decreased with increasing MET-hours of physical
activity for all specific time periods. However, the associa-
tion was statistically significant for physical activity in the
first 10 years after menarche (Ptrend = 0.02), but not for
physical activity in other time periods (all Ptrend ≥ 0.05).
Discussion
Our analyses for tumor marker-specific breast cancer risk
showed that lifetime recreational physical activity was
only associated with a lower risk of ER+ and of HER2
breast cancer. Further analyses by the various combina-
tions of ER, HER2, PR, and p53, revealed that the protec-
tive effect of lifetime recreational physical activity on
breast cancer risk varied only by HER2 status.
The results of three previous studies that have exam-
ined the association between physical activity and breast
cancer subtypes defined by ER, PR, and HER2 status are
mixed [3, 35, 36]. The Women’s Health Initiative (WHI)
Cohort Study reported that the risk of ER+ and TN
breast cancers were both inversely associated with baseline
recreational physical activity (MET-hours/week), but no
data were reported on whether HER2 status alone
impacted the inverse association between recreational
physical activity and breast cancer risk [36]. Two case–
control studies evaluated whether physical activity is asso-
ciated with breast cancer risk according to HER2 status
[3, 35]. In a population-based case–control study of post-
menopausal women, leisure-time physical activity (MET-
hours/week) after age 50 years was associated with lower
risk of ER+/PR+ breast cancer, but not ER/PR breast
cancer; risk did not vary further by HER2 status [3]. In
another population-based case–control study of women
aged 20–54 years [35], women whose exercise activity in
the year before interview was at or above the median level
had a lower risk for all subtypes of breast cancer defined
by ER/PR/HER2, except for the ER/PR+/HER2+ subtype.
Our analyses showed that recreational physical activity
was inversely associated with reduced risk for HER2 but
not HER2+ breast cancer. Discrepancies in the results by
study may be due to different time periods of physical
activity assessed. These time periods included physical
activity after age 50 years up to reference date (date of
diagnosis for cases and date of interview for controls) [3]
and physical activity only in the year before interview
[35]. In our study, a more comprehensive measure of
physical activity was evaluated including physical activity
over a lifetime plus four specific time periods of life.
Moreover, the discrepancies in the results by study could
also be due to use of different cut-points to define the
status of HER expression or different methods to assay
HER2. For example, one study defined HER2+ as tumors
which were judged to be low/moderate or high intensity
staining on IHC [35]. In our study, we defined HER2+ as
moderate or high intensity staining on IHC. Our data
showed that recreational physical activity was not associ-
ated with breast cancers that were either moderate or
strong expressers of HER2.
Moreover, the case–case comparison approach is a use-
ful exploratory tool to examine etiologic heterogeneity
between subtypes [51]. Heterogeneity between subtypes
may represent different etiologic mechanisms for the two
groups of cases or it may represent a different strengths
of effect operating through the same mechanism [51].
One [35] of the three previous studies on this topic [3,
35, 36] reported case–case comparison data for the sub-
types defined by ER/PR/HER2 (each subtype compared to
ER/PR+/HER2). Recreational physical activity for ER/
PR+/HER2+ cases was more likely to be at or above the
median level of activity than for ER/PR+/HER2 cases
(OR = 1.73, 95% CI = 1.00–3.00) [35]. In line with pre-
vious findings, our case–case comparisons showed that
HER2 cases were less likely than HER2+ cases to have a
higher annual MET hour/week of recreational physical
activity, although the negative association was only statis-
tically significant for physical activity in the first 10 years
after menarche.
HER2, a transmembrane tyrosine kinase receptor pro-
tein, normally cooperates with three other HER receptors
in various growth signaling pathways to regulate cell
growth, differentiation, and survival [52]. HER2 is over-
expressed in approximately 15–25% of breast carcinoma
specimens [53]. The most common mechanism leading to
HER2 overexpression is amplification of the HER2 proto-
oncogene [54, 55] located on chromosome 17q21.
Tumors that overexpress HER2 are more likely to grow
rapidly, metastasize, and be resistant to endocrine therapy
[56]. Overexpression of HER2 may disrupt normal cell
control mechanisms, potentially leading to the formation
of aggressive tumor cells [57, 58]. Studies on stem/pro-
genitor cells as initiators of breast cancer showed that
HER2 overexpression increased the stem/progenitor cell
populations of normal and malignant mammary cells.
Increasing the stem/progenitor cell population may lead
to tumorigenesis, tumor invasion, or metastasis [59].
Although we have no explanation as to why the associa-
tion between physical activity and breast cancer varied by
HER2 status in our study, it is plausible that recreational
physical activity may not exert a protective effect on
breast cells if normal cell control mechanisms have been
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disrupted or if overexpression of HER2 has increased the
stem/progenitor cell population. Further research will be
needed to explore the possible mechanisms.
This study has several limitations. First, although recall
error was minimized by assessing exercise activity in con-
junction with the completion of a calendar of life events
to facilitate recall and by recording activities at every age
throughout life in the Women’s CARE Study, we cannot
rule out the possibility that women’s history of activity
was misclassified, especially for years in the distant past.
This classification could differ between case participants
and control participants, but it is unlikely to differ
between HER2 and HER2+ case participants. Second,
we did not request tissue for all eligible case participants
due to funding constraints. We compared our measures
of physical activity for eligible case participants with and
without known ER, PR, HER2, and p53 status. No statis-
tically significant differences were detected (data not
shown). Third, IHC was used to assess HER2 protein
overexpression without validation by FISH analysis in this
study. Based on previous validation results from the same
pathology laboratory, 7.4% of breast cancers with HER2
gene amplification in FISH analysis were falsely negative
by 10H8-IHC (scored as 0 or 1+) [44]. If these results
hold true for the current study, we could have underesti-
mated the negative association between the recreational
activity and HER2–breast cancer. The previous validation
also showed 9.7% of breast cancers without HER2 gene
amplification in FISH analysis were falsely positive by
10H8-IHC (scored as 2+ or 3+); this could have led to a
bias toward the null if a positive association truly exists
between recreational physical activity and HER2+ breast
cancer risk. Fourth, due to funding limitations, we evalu-
ated p53 protein expression, but not p53 mutations.
Although previous research shows that p53 protein
expression and p53 mutation status determined by FISH
analysis are strongly correlated [46], our assessment of
p53 protein expression by IHC may have misclassified
some tumors, which could have masked potential effect
modification by p53 status in analyses of the association
of recreational physical activity and breast cancer risk.
Fifth, that recreational physical activity was not associated
with HER2+ subtype could have been due to a lack of
statistical power, as HER2+ occurs less frequently than
HER2–subtype (in our study, n = 216 HER2+ vs. n = 979
HER2). However, the majority of our risk estimates of
HER2+ subtype associated with recreational physical
activity are above 1 and it is plausible that the lack of an
inverse relationship is real. Sixth, we were unable to
examine the effect of either occupational activity or
household activity on breast cancer risk because of the
lack of questionnaire data on these exposures. For the
same reason, we did not adjust for dietary factors in our
models. Seventh, our exploratory analyses assessing
whether the associations of specific receptor subtypes of
breast cancer with lifetime recreational physical activity
vary by menopausal status showed that the overall result
was defined by the result among premenopausal women
as we observed no association among postmenopausal
women. It is noteworthy that the number of postmeno-
pausal women in the Women’s CARE Study was substan-
tially lower than the number of premenopausal women
due to the Study’s design. The Women’s CARE Study was
restricted to women ages 35–64 years in order to focus
on the impact of oral contraceptives on breast cancer risk
among older premenopausal and perimenopausal women,
as well as women who had menopause within the recent
past few years. Hence, fewer postmenopausal women were
recruited into the study, thereby limiting our ability to
address whether the observed results vary by menopausal
status or by HT use. Lastly, when we stratified by several
tumor markers simultaneously, case numbers were small
leading to insufficient statistical power rather than to
Type I error. Therefore, we did not adjust P values for
multiple testing.
In conclusion, we found that the association between
recreational physical activity and risk of breast cancer var-
ied by HER2 status. Our conclusion is based on the
exploratory data from a population-based case–control
study using two-sided statistical tests without correction
for multiple testing. Further research will be needed to
confirm that this association is limited to HER2–breast
cancers and to explore possible biological mechanisms. If
our findings are confirmed and biological mechanisms are
elucidated, this could advance our understanding of what
controls whether a tumor has a HER2 gene mutation.
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